Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes

Last updated: October 17, 2019
Sponsor: Universidad de Guanajuato
Overall Status: Active - Recruiting

Phase

3

Condition

Diabetes And Hypertension

Diabetes Mellitus Types I And Ii

Diabetes Prevention

Treatment

N/A

Clinical Study ID

NCT04131582
CI/HRAEB/2017/049
  • Ages 18-65
  • All Genders

Study Summary

Type 2 diabetes is a worldwide epidemic disease, and preventive strategies are needed to face this health problem. The goal of this trial is to evaluate the effect of empagliflozin + linagliptin + metformin + lifestyle on physiopathological parameters, sush as glucose metabolism, insulin resistance, pancreatic beta cell function and cardiovascular function in patients with impaired fasting glucose plus impaired glucose tolerance, during 12 months

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with prediabetes, defined for the existence impaired glucose tolerance (glucose between 140 and 199 mg/dL at the 2 hours of the Oral Tolerance Glucose Test (OGTT) with impaired fasting glucose (fasting glucose between 100 and 125 mg/dL)

  • Patients who accept to participate in the study and sign the informed consent letter.

Exclusion

Exclusion Criteria:

  • Patients with diagnosed Type 2 Diabetes previously or detected during the OGTT

  • Patients in actual treatment or during the last 3 months with metformin, pioglitazoneor another antidiabetic drug, including insulin

  • Serum creatinine > 1.6 mg/dL

  • Hypertriglyceridemia very high (>500 mg/dL)

  • Pregnant women

  • Altered arterial hypertension (Systolic >180 mmHg or Diastolic >105 mmHg)

  • Excessive alcohol intake, acute or chronic

  • Medications or medical conditions that affect glucose homeostasis (thiazides, betablockers, glucocorticoids for systemic use, weight-reducing drugs or anorexigenics,Cushing´s syndrome, thyrotoxicosis

Study Design

Total Participants: 34
Study Start date:
September 01, 2019
Estimated Completion Date:
December 30, 2020

Study Description

The main goal of this clinical trial is to compare the effect of two different treatments during 12 months:

  1. Lifestyle modification program + metformin 850 mg twice daily

  2. Lifestyle modification program empagliflozin (12.5 mg) + metformin (850 mg) once daily plus linagliptin (2.5 mg) + metformin (850 mg) once daily On the following parameters, after 12 months of treatment

  1. Glucose metabolism, evaluated by oral glucose tolerance test 2) Insulin resistance evaluated by the oral glucose tolerance 3) Insulin secretion, evaluated by the oral glucose tolerance 4) Pancreatic beta cell function, evaluated by the oral glucose tolerance test 5) Cardiovascular function, evaluated by standard echocardiography by left ventricular ejection fraction

All the patients will have a basal evaluation with an oral glucose tolerance test, lipid profile and body composition measurement by dual energy X-ray absorptiometry (DEXA). After the basal evaluation, if the patients results with impaired fasting glucose and impaired glucose tolerance, they will be invited to the intervention phase where they will be randomized to one of the two treatment groups.

Patients will have a follow-up visit every month to review the adherence to the lifestyle modification program and to the medication, and every 6 months an OGTT. After 12 months , patients will repeat the same evaluation performed at basal.

Connect with a study center

  • Universidad de Guanajuato

    León, Guanajuato 37670
    Mexico

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.